DOT lenses now available for early access in the UK

SightGlass Vision’s Diffusion Optics Technology (DOT™) myopia control spectacle lenses are making further progress around the globe with its recent launch into early access in the UK, which will provide clinicians and families an avenue to help fight the growing epidemic of childhood myopia, according to a news release.¹

“Introducing DOT lenses in a new country is always an exciting moment for us because it means we can offer even more eye care professionals this globally trusted tool to protect their young patients’ vision,” said Andrew Sedgwick, CEO of SightGlass Vision, in the release. “With over one million children already having worn DOT ^™ lenses, we look forward to working with the UK optical community to expand access, intervene early, and help preserve children’s eye health with this highly effective technology.”

Much like the rest of the world, the prevalence of myopia in children in the UK is only growing, having more than doubled in the past 50 years. Additionally, the onset of myopia is starting at a younger age in the region, increasing pediatric patients’ likelihood of higher myopia later in life. Every diopter of myopia progression increases the risk of serious eye conditions, whereas every diopter saved can reduce future eye health risk by up to 40%.¹

In light of the early access, SightGlass Vision will be hosting a webinar on October 15 titled “Manage Contrast to Manage Myopia: Introducing DOT Lenses.” The webinar will provide the opportunity for UK eye care providers to learn more about the lens design, the supporting clinical research, and ask questions to senior members of the company’s team during a live Q&A. Registration for the webinar is open on SightGlass Vision’s website.¹

This early access in the UK follows a total of 1 million children recorded to have worn the DOT lenses.First made available in 2021, the lenses have experienced significant momentum and have reached a major milestone that reflects the need for myopia control solutions, SightGlass Vision said in a news release.²

The DOT lens has been launched across Asia-Pacific, Europe, and North America, with an estimated 500,000 fitted with DOT lenses in 2025 alone, as estimated by global sales data. Additionally, SightGlass Vision’s patent-protected technology has made its commercial debut in several markets around the globe, including China, the Netherlands, Israel, Canada, and Spain. The lens is also involved in preliminary market trials in other countries.²

Earlier this year, SightGlass Vision released preliminary results from a clinical study that found that DOT 0.2 spectacle lenses were highly effective for myopia management, achieving 75% efficacy in children after 12 months in China. Additionally, 93% of children expressed positive feedback about their DOT lens glasses.¹ Previous findings have demonstrated that the DOT lenses significantly reduce myopia progression over 36 months in children as young as 6 years, with 65% of children having no clinically meaningful myopia progression after 1 year. Additionally, myopia progression was reduced by 59% over 2 years when the lenses were worn full-time.²

References:

1. DOT myopia control spectacle lenses available for early access in the UK. News release. SightGlass Vision. September 22, 2025. Accessed September 22, 2025.

2. Joy J. DOT lenses for slowing myopia progression worn by a total of 1 million children. Optometry Times. August 22, 2025. Accessed September 22, 2025. https://www.optometrytimes.com/view/dot-lenses-for-slowing-myopia-progression-worn-by-a-total-of-1-million-children